Bailard Inc. Decreases Stock Position in DexCom, Inc. $DXCM

Bailard Inc. cut its position in DexCom, Inc. (NASDAQ:DXCM) by 17.2% in the 4th quarter, Holdings Channel.com reports. The firm owned 46,699 shares of the medical device company’s stock after selling 9,690 shares during the quarter. Bailard Inc.’s holdings in DexCom were worth $3,099,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Trust Co. of Vermont boosted its stake in shares of DexCom by 14.8% in the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after purchasing an additional 145 shares during the period. CVA Family Office LLC boosted its stake in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 147 shares during the period. IFP Advisors Inc boosted its stake in shares of DexCom by 24.7% in the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock valued at $61,000 after purchasing an additional 178 shares during the period. Personal CFO Solutions LLC boosted its stake in shares of DexCom by 5.0% in the third quarter. Personal CFO Solutions LLC now owns 3,864 shares of the medical device company’s stock valued at $260,000 after purchasing an additional 185 shares during the period. Finally, Inspire Advisors LLC boosted its stake in DexCom by 2.5% during the 3rd quarter. Inspire Advisors LLC now owns 7,926 shares of the medical device company’s stock valued at $533,000 after acquiring an additional 194 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Robert W. Baird set a $80.00 price objective on shares of DexCom in a research note on Friday, May 1st. Raymond James Financial set a $81.00 price target on DexCom in a research report on Friday, May 1st. BTIG Research reissued a “buy” rating and set a $85.00 price target on shares of DexCom in a research report on Monday, March 9th. Weiss Ratings raised DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, March 4th. Finally, Canaccord Genuity Group set a $100.00 target price on shares of DexCom and gave the stock a “buy” rating in a report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $83.22.

DexCom Stock Up 3.1%

DXCM stock opened at $61.14 on Wednesday. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The firm’s 50-day simple moving average is $64.30 and its 200 day simple moving average is $66.09. The stock has a market cap of $23.59 billion, a PE ratio of 26.13, a price-to-earnings-growth ratio of 1.02 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter last year, the company earned $0.32 EPS. The company’s revenue for the quarter was up 15.0% compared to the same quarter last year. As a group, sell-side analysts predict that DexCom, Inc. will post 2.56 EPS for the current year.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total transaction of $107,168.00. Following the transaction, the executive vice president owned 111,204 shares of the company’s stock, valued at approximately $7,010,300.16. This trade represents a 1.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.28% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.